GREY:ICOTF - Post by User
Post by
db2067on Jan 28, 2021 9:20pm
249 Views
Post# 32416839
UBC Global Health Conference
UBC Global Health Conference UBC Global Health Conference Jan 27 2021 https://www.bcchr.ca/sites/default/files/global-health-conference/poster-no.-13-kishor-wasan.pptx "These data suggest that we have developed a novel oral amphotericin B formulation that is safe and tolerable following single and multiple dosing to healthy human subjects. In addition, the prolonged plasma half-life and increased AUC observed in both the phase 1a and 1b human clinical studies suggests that ICo-19 has a long circulation time which may result in the ability of the formulation to increase and sustain Amphotericin B tissue concentrations within infected tissues without the associated GI, liver and kidney toxicity."